[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-269290-105":59,"doc-detail-269290-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","northstar-select-results-sample-report","Northstar Select Results - Sample Report","","Northstar Select sample report presents a genomic test summary for a patient diagnosed with Non-Small Cell Lung Carcinoma, including specimen and report dates, internal identifiers, and physician ordering details. The document lists detected informative genomic alterations and summarizes associated FDA-approved and guideline-recommended therapies, along with resistance and clinical-trial matching information. It also evaluates guideline-recommended genes and provides variant-level interpretation for key findings such as CHEK2 R145W and KRAS G13C.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/northstar-select-results-sample-report/269290/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/northstar-select-results-sample-report/269290.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-15",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"What does the report provide for each variant under Variant Details?","Question",{"text":113,"@type":114},"For each variant, the report explains gene function and clinical relevance, then specifies the variant’s molecular context (e.g., amino-acid change, domain impact) and how it may relate to therapy options.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},269290,1789450011,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":122,"read_time":136,"preview_page_count":4},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","SELECT  \nT 833.537.1819  \nF 833.874.0918  \n[E](E support@northstaronc.com)[ support@northstaronc.com](E support@northstaronc.com)  \n[northstaronc.com](northstaronc.com)  \nPatient  \nName  \nDate of Birth (Age) Assigned Sex at Birth Diagnosis  \nMedical Record \\# Internal Patient ID  \nJane Jones 11/27/1940 (83 yrs) Female  \nNon-Small Cell Lung Carcinoma ID400231  \n10000090  \nSample  \nSpecimen Type Collection Date Receipt Date Accession ID Report Date Test Number  \nBlood 01/05/2024  \n01/06/2024 V010900AA001-1 02/01/2024  \n1  \nPhysician  \nOrdering Physician Medical Facility Address  \nPhone Fax  \nJohn Smith BillionToOne Inc  \n1035 O'Brien Drive Menlo Park, California 94025  \n(833) 537-1819  \n(833) 874-0918  \nNorthstar Select Results  \nlfoterrmatiigendenimfieicd   \n\n| \u003Cbr>Summary of Informative Genomic Alterations\u003Cbr>Detected Genomic Findings§\u003Cbr>Associated FDA-Approved and/or Guideline Recommended Therapies circle-check Approved in indication circle-check Approved in other indication circle-xmark Associated with resistance\u003Cbr>Clinical Trials§§\u003Cbr>VAF /\u003Cbr>Copy number |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| \u003Cbr>CHEK2 R145W |  | • enzalutamide/talazoparib\u003Cbr>• olaparib |  | 5 | 0.74% |\n| \u003Cbr>KRAS G13C |  |  | • afatinibG • erlotinibG\u003Cbr>• gefitinibG • osimertinibG\u003Cbr>• panitumumab | 5 | 0.25% |\n| \u003Cbr>MET V1206L |  |  |  | 0 | 0.09% |\n\nG Treatment listed is based upon recommendation from professional guidelines only. Please consult professional guidelines and FDA indications for complete details.  \n§ For additional variant information, please see the Variant Details section of the report. Variants of Unknown Significance (VUS) and Genes with copy number signal indicating potential for aneuploidy are reported after the Variant Details section of the report.  \n§§ Clinical trials are matched within 500 miles of the ordering physician, based on detected genomic alterations and provided patient demographics. For additional options, [please visit](please visit www.clinicaltrials.gov)[ www.clinicaltrials.gov](please visit www.clinicaltrials.gov).  \n| Summary of Guideline-Recommended Genes Evaluated |\n| --- |\n| The following guideline-recommended genes for Non-Small Cell Lung Carcinoma were evaluated. Variants not listed in the tables above are considered 'Not Detected'. For a complete list of genes tested, refer to the Methods section of the report.\u003Cbr>|\n\nBillionToOne, Inc. 1035 O’Brien Drive, Menlo Park, CA 94025 CLIA \\#: 05D2275351. CLF-90008579. Lab Director: Joseph Michael Anderson, MD Version: 2.4.0-5cfccc3 Page 1 of 7  \nSELECT  \nT 833.537.1819  \nF 833.874.0918  \n[E](E support@northstaronc.com)[ support@northstaronc.com](E support@northstaronc.com)  \n[northstaronc.com](northstaronc.com)  \nPatient Name Diagnosis  \nJane Jones  \nNon-Small Cell Lung Carcinoma  \nDate of Birth (Age) Internal Patient ID  \n11/27/1940 (83 yrs) 10000090  \nAssigned Sex at Birth Report Date  \nFemale 02/01/2024  \nClinical Trial Availability  \nClinical trial matches are displayed based upon somatic variant detection and patient demographic and diagnostic information provided on the test requisition form. Trials are matched within 500 miles of the ordering provider ’s location. This list is neither comprehensive nor a guarantee of eligibility, as many other requirements must be met prior to enrollment.  \nFor further details on eligibility, please visit www.[clinicaltrials.gov](clinicaltrials.gov) and enter the NCT\\# .  \nBillionToOne, Inc. 1035 O’Brien Drive, Menlo Park, CA 94025 CLIA \\#: 05D2275351. CLF-90008579. Lab Director: Joseph Michael Anderson, MD Version: 2.4.0-5cfccc3 Page 2 of 7  \nSELECT  \nT 833.537.1819  \nF 833.874.0918  \n[E](E support@northstaronc.com)[ support@northstaronc.com](E support@northstaronc.com)  \n[northstaronc.com](northstaronc.com)  \nPatient Name Diagnosis  \nJane Jones  \nNon-Small Cell Lung Carcinoma  \nDate of Birth (Age) Internal Patient ID  \n11/27/1940 (83 yrs) 10000090  \nAssigned Sex at Birth Report Date  \nFemale 02/01/2024  ","cbCaiod6BR0dtUav","https://ap.wps.com/l/cbCaiod6BR0dtUav","pdf",243477,"English","# Summary of Informative Genomic Alterations\n## Summary of Guideline-Recommended Genes Evaluated\n# Clinical Trial Availability\n# Variant Details","[{\"question\":\"What does the report provide for each variant under Variant Details?\",\"answer\":\"For each variant, the report explains gene function and clinical relevance, then specifies the variant’s molecular context (e.g., amino-acid change, domain impact) and how it may relate to therapy options.\"}]","Northstar Select Results - Sample Report | PDF",18]